#Italy #London #Urology #Esaote #PAM Technology

Esaote Launches Revolutionary PAM Technology at EAU 2026

At the 41st Annual Congress of the European Association of Urology (EAU) in London, the Esaote Group, a prominent Italian innovator in medical imaging, unveiled its latest advancement aimed at enhancing urological care—the Prostate Attention Map (PAM) technology. This state-of-the-art innovation aims to significantly elevate precision in prostate imaging and diagnosis.

Esaote took center stage to present the PAM, which is integrated into the MyLab™E85 GTS Edition. This technology is designed specifically for the urology sector, promising to refine how medical professionals analyze prostate MRI volumes. During the congress, Esaote also introduced the new MyLab™C30 GTS ultrasound system, expanding the reach of high-quality imaging into more accessible environments.

With a focus on fostering efficiency and clinical excellence, the PAM technology's core function lies in its capability to perform automatic analyses and pinpoint suspicious areas within prostate images. This allows urologists to make more informed decisions and enhances targeted treatment approaches. As Marta Daniel, the Manager of Guided Therapy Products and Clinical Solutions at Esaote, noted, “The PAM technology seamlessly integrates with Esaote’s UroFusion software, which is tailored to facilitate focused guidance during targeted prostate biopsies.”

Additionally, the integration of artificial intelligence in the UroFusion package provides a workflow that remains consistent in duration with standard biopsy examinations but markedly increases the reliability and accuracy of the biopsy processes. This dual edge of efficiency and precision could lead to improvements in patient outcomes through enhanced diagnostic capabilities.

Esaote’s commitment to education also shone brightly at EAU 2026, where the company hosted hands-on training sessions for TP biopsies and MRI-US fusion, led by internationally recognized specialists. These sessions allowed attendees to engage directly with the latest advancements in urological imaging technology and increase their practical knowledge of the PAM and UroFusion solutions.

The participation of Esaote at EAU 2026 showcases not only a new leap forward with the PAM technology but also underscores a significant expansion of their Guided Therapy Solutions (GTS) product lineup. By providing reliable, intelligent, and clinically relevant imaging solutions, Esaote continues to reaffirm its dedication to empowering urologists with tools that ensure advanced image quality and intuitive operational workflows.

With the introduction of PAM and other innovative systems tailored for urology, Esaote reinforces its market leadership in medical imaging—transforming imaging practices and offering solutions that are responsive to the evolving needs of healthcare professionals worldwide. As Esaote looks ahead, the organization embodies a vision wherein enhanced imaging accuracy fosters improved clinical outcomes for patients undergoing prostate evaluations.

Esaote’s impact resonates beyond Italy, with a robust presence in over 100 countries. Employing approximately 1,300 staff members across various global locations, including Genua and Florence, the company remains at the forefront of medical imaging advancements. You can learn more about Esaote's comprehensive product offerings and their commitment to medical innovation by visiting their official website at www.esaote.com.